Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival.
Immune checkpoint inhibitor therapy
NSCLC
autoimmune toxicity
tumor-associated antigen
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
3
12
2021
pubmed:
4
12
2021
medline:
4
1
2022
Statut:
epublish
Résumé
Immune checkpoint inhibitors (ICIs) have improved the survival of patients with non-small cell lung cancer (NSCLC) by reinvigorating tumor-specific T cell responses. However, the specificity of such T cells and the human leukocyte antigen (HLA)-associated epitopes recognized, remain elusive. In this study, we identified NSCLC T cell epitopes of recently described NSCLC-associated antigens, termed keratinocyte differentiation antigens. Epitopes of these antigens were presented by HLA-A 03:01 and HLA-C 04:01 and were associated with responses to ICI therapy. Patients with CD8
Identifiants
pubmed: 34858733
doi: 10.1080/2162402X.2021.2006893
pii: 2006893
pmc: PMC8632109
doi:
Substances chimiques
Antigens, Differentiation
0
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2006893Informations de copyright
© 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.
Déclaration de conflit d'intérêts
No potential conflict of interest was reported by the author(s).
Références
Nat Commun. 2017 Feb 01;8:14381
pubmed: 28146145
Nat Commun. 2020 Jan 30;11(1):603
pubmed: 32001676
Oncoimmunology. 2017 Feb 6;6(3):e1284722
pubmed: 28405515
Methods Mol Biol. 2007;409:75-93
pubmed: 18449993
Nat Rev Cancer. 2003 Sep;3(9):666-75
pubmed: 12951585
Nat Cancer. 2020 Feb;1(2):210-221
pubmed: 32110781
Cancer Immunol Res. 2016 Oct;4(10):835-844
pubmed: 27587469
Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):E166-75
pubmed: 25548167
JAMA Oncol. 2019 Jul 1;5(7):1043-1047
pubmed: 31021392
JCI Insight. 2016 Jul 7;1(10):e86837
pubmed: 27699219
J Immunol. 2017 Nov 1;199(9):3360-3368
pubmed: 28978689
Eur J Cancer. 2019 Jan;107:8-14
pubmed: 30529903
Lancet Oncol. 2012 Jul;13(7):e301-10
pubmed: 22748269
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
Mol Cell Proteomics. 2013 Jul;12(7):1853-64
pubmed: 23538226
Gen Thorac Cardiovasc Surg. 2009 Sep;57(9):449-57
pubmed: 19756930
Oncotarget. 2015 Feb 20;6(5):2812-26
pubmed: 25739119
J Exp Med. 1995 Feb 1;181(2):799-804
pubmed: 7836932
Methods Mol Biol. 2019;1988:123-136
pubmed: 31147937
Nature. 2017 Jul 6;547(7661):94-98
pubmed: 28636589
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Nat Cancer. 2020 Feb;1(2):197-209
pubmed: 33305293
Nat Methods. 2007 Nov;4(11):923-5
pubmed: 17952086
Lancet Oncol. 2015 Aug;16(8):908-18
pubmed: 26115796
Front Immunol. 2017 Mar 14;8:278
pubmed: 28352270
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Nat Rev Clin Oncol. 2019 Sep;16(9):563-580
pubmed: 31092901
Proc Natl Acad Sci U S A. 2017 Nov 28;114(48):E10409-E10417
pubmed: 29138313